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Stromelysin-3 Expression Promotes Tumor Take in Nude Mice
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Stromelysin-3 (ST3) is a matrix metalloproteinase ex-
pressed in human carcinomas in ways suggesting that it
may play a role in tumor progression. To test this possibil-
ity, we have performed gene transfer experiments using
both anti-sense and sense ST3 expression vectors, and ma-
lignant cells either expressing (NIH 3T3 fibroblasts) or not
(MCF7 epithelial cells) endogenous ST3. We have com-
pared the ability of parental and transfected cells to cause
subcutaneous tumor development in nude mice. 3T3 cells
expressing anti-sense ST3 RNA showed reduced tumorige-
nicity, and MCF7 cells expressing mouse or human ST3
were associated with reduced tumor-free period leading to a















once established, the ST3-expressing tumors did not grow
faster than those obtained with the parental MCF7 cell line.
In addition, tumors obtained after sub-cutaneous injection
of ST3-expressing or nonexpressing cells did not exhibit ob-
vious histological differences, and careful examination did
not reveal any local invasive tissue areas nor systemic me-
tastases. These in vivo observations were in agreement with
those obtained in vitro showing that ST3 expression did not
modify proliferative nor invasive properties of transfected
cells. Altogether, these results indicate that ST3 expression
promotes tumor take in nude mice, presumably by favoring
cancer cell survival in a tissue environment initially not per-
missive for tumor growth. These findings represent the first
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 are members of a family
of zinc-dependent endopeptidases with a broad spectrum of
proteolytic activities toward extracellular matrix (ECM) com-
ponents (1–3). These enzymes include collagenases, gelati-
nases, stromelysins, and membrane-type MMPs (1–7). They
are expressed as proenzymes which are processed to active
forms through proteolytic cleavage, and their activities are
controlled by physiological tissue inhibitors of metalloprotein-
ases (TIMPs). It has been proposed that imbalance between
MMPs and TIMPs is implicated in various physiological and
pathological tissue remodeling processes, notably those enabling
tumor progression and leading to metastasis (8–9). Experi-
mental evidences supporting this possibility were presented by
Khokha et al. (10) who demonstrated that the down-regulation
of TIMP-1 levels by anti-sense (AS) RNA transfection in 3T3
cells increased their tumorigenic and metastatic potential in
nude mice. Inversely, the secretion of functional TIMP-2 in
stably transfected cells was found to result in a marked de-
crease in tumor growth rate and local invasiveness (11). More
recently, matrilysin over-expression in human prostate cancer
cells was reported to increase their invasive potential in SCID
mice (12). Gene transfer experiments using both sense (S) and
AS expression vectors have also shown that the level of matri-
lysin expression was a critical factor in the aptitude of colon
cancer cells to migrate through basement membrane-like ma-
trices in vitro (13) and to generate tumors in vivo, in nude mice
(14). Similarly, the expression of gelatinase A or B was found
to confer a metastatic phenotype to transfected transformed
cells (15, 16). 
Stromelysin-3 (ST3) was first described in fibroblastic cells
of invasive breast carcinoma and classified as a member of the
MMP family on the basis of sequence homologies (17). ST3 ex-
pression was thereafter observed in most other types of human
invasive carcinomas and in some precursor lesions (18, 19, and
references therein). Strong ST3 gene expression has been cor-
related with increased local aggressiveness of tumors (20, 21),
and high levels of ST3 RNA were found to be predictive of re-
currence in breast carcinomas (22). ST3 over-expression was
also shown to be associated with tissue remodeling occurring
in physiological conditions such as embryonic development
(23), amphibian metamorphosis (24), mammary gland involu-
tion (25), wound healing (20), and cycling endometrium (26).
Although these observations suggest that ST3 may play a role
in ECM remodeling, putative mature forms of human ST3
(hST3) appear unable to degrade any major ECM component
(27, 28). Furthermore, it has been recently demonstrated that
ST3 was predominantly secreted as a potentially active form,
pro-ST3 being intracellularly processed by a furin-dependent
proteolytic cleavage (29). ST3 thus differs from other MMPs
which must be activated extracellularly, indicating that ST3
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may have a unique role in tissue remodeling processes, includ-
ing those associated with tumor progression.
In the present study, we have subcutaneously (S.C.) in-
jected nude mice with malignant cells stably transfected with
either AS or S ST3 cDNA constructs, in order to evaluate the
effect of ST3 expression on tumorigenicity in vivo. Using the
same cells, we have also tested whether ST3 could modulate











 plasmid was obtained by inserting in the AS orientation, a 360-
bp BamHI fragment (nucleotides 1 to 360) of mouse ST3 (mST3)




 vector in which expression is under the
control of the cytomegalovirus (CMV) promoter (provided by B. Vo-





a 1504-bp NsiI fragment, containing the entire coding sequence of
mST3, was excised and ligated to a 8-mer BamHI–NsiI adaptor and









 plasmid, a 1680-bp SpeI–XhoI frag-
ment of hST3 cDNA (17), containing the entire coding sequence, was




 vector modified by insertion of a polylinker containing




plasmid, a 1681 bp EcoRI fragment of hST3 cDNA was inserted in S




 vector in which expres-
sion is under the control of the SV40 promoter (31). 
 
Obtention of stably transfected cell lines.
 
Malignant NIH 3T3 (ob-
tained from B. Pettmann, Strasbourg, France) (32) and MCF7 (ATCC
HTB 22) cells were cultured in Dulbecco’s modified Eagle’s medium
(DME) containing 10% fetal calf serum. 3T3 cells were electropo-





















































g). Transfectants were then selected with the neo-
mycin analogous G418 (400 µg/ml; GIBCO BRL, Gaithersburg, MD)











RNA isolation and analysis.
 
Total RNA was prepared from cul-
tured cells using acid guanidinium thiocyanate-phenol-chloroform
extraction (33). RNAs were fractionated by electrophoresis through
1% agarose gel in the presence of formaldehyde, and transferred to
nylon membranes (Hybond N; Amersham). Filters were acidified for
10 min in 5% CH3COOH and stained for 10 min (0.004% methylene
blue, 0.5 M CH3COONa, pH 5.0) before hybridization. Northern blots































Conditioned media were obtained by incubating
subconfluent cells in serum-free DME. After 48 h incubation, media














 for 2 h, protein pellets were resuspended in 50 mM Tris-HCl













C, for 3 h. Protein concentrations were deter-
mined using the BioRad kit (BioRad Laboratories). Protein samples
were analyzed by SDS-PAGE (12%) under reducing conditions. For
immunoblot analysis, proteins were transferred after electrophoresis
to nitrocellulose filters which were incubated with monoclonal anti-
body 5ST-4C10 which recognizes the ST3 catalytic domain (35).
Bound antibodies were visualized using a peroxidase-labeled goat an-
tibody raised against mouse IgG, followed by Enhanced Chemilumi-




Subconfluent NIH 3T3 cells were trypsinized,




 for 5 min, and resuspended in serum-free








cells was S.C. in-
jected into 6–8-week-old female nude MF1 nu/nu mice (Harlan,
France). Subconfluent MCF7 cells were trypsinized, washed twice,




 for 5 min. Cells resus-
pended in cold serum-free DME were mixed with an equal volume of
cold matrigel (10 mg/ml) prepared from the Engelbreth-Holm-









 cells was S.C. injected into 6–8-week-old female
nude mice, previously implanted with Silastic capsules (Dow Corn-
ing) containing estradiol (37). 
Injected mice were examined every 2 d for tumor apparition and
tumor volume was calculated as previously described (37). Tumor in-
cidence was defined as the percentage of mice presenting a tumor, in










lower than 0.05 were considered as significant. All mice were autop-
sied. One half of each tumor was immediately frozen in liquid nitro-
gen for RNA analysis. The second tumor half, the lungs and the liver
were fixed in phosphate buffered formalin (4%) and embedded in
paraffin. Histological examination was performed on hematoxilin-
eosin stained sections. Immunohistochemical localization of mST3
was performed using polyclonal antibody 612, obtained by rabbit im-
munization with recombinant mST3 extracted from bacterial inclu-
sion bodies (28), whereas the immunohistochemical localization of
hST3 was performed using rabbit polyclonal antibody 349 as previ-
ously described (21). Tissue sections were also stained with a rabbit
polyclonal antibody raised against human pS2 (39), in order to check
for the presence of metastatic MCF7 cells in mouse lungs and liver. 
 
Cell proliferation and in vitro invasion assays.
 
Cell proliferation was
evaluated by counting trypsinized cells every 2 d using a Coulter
counter (Coultronics France). 
Chemoinvasion assays (40) were performed using Transwell
chambers (Costar Corp., Cambridge, MA) with polycarbonate mem-

















) were harvested by trypsinization,
resuspended in serum-free DME containing 0.2% bovine serum albu-
min (ICN, Flow) and added to the upper compartment of Transwell





taining 20% fetal calf serum and 2% bovine serum albumin as





rinsed in phosphate buffered saline, fixed in paraformaldehyde 4%
and permeabilized in ice-cold methanol before staining with hema-
toxylin-eosin. Cells on the upper face of the filters were wiped away
with a cotton swab, and those on the lower face were counted on 24




400. Three independent experi-
ments were conducted, each using three Transwell chambers.
For collagen invasion assays, cells were seeded onto a polymer-




C, the number of
cells that had invaded into the collagen gel was counted as previously
described (41).
Invasion assays into chick heart were based on the in vitro con-
frontation between cell aggregates and precultured chick heart frag-
ments in organ culture (42). The interaction between tested cells and
chick heart fragments was evaluated by microscopic examination of
serial sections fixed in Bouin Holland’s solution, embedded in paraf-




Decreased tumor incidence using cells down-regulated for mST3
expression.
 
A malignant mouse NIH 3T3 fibroblastic cell line,














ods) in order to downregulate the expression of the mST3 en-
dogenous gene. Different neomycin resistant clones were es-
tablished. Three of them were found to express AS transcripts
with the expected size, either at high (3T3/7.5 and 3T3/4.6) or




). The other clones, in-
cluding the 3T3/2.1 and 3T3/1.1 clones, did not express AS








). In addition, the NIH 3T3 cell




 vector alone and gave rise to









Nude mice were S.C. inoculated with an identical number
of cells of each clone. After 3 wk, tumors were observed in 50
and 20% of injection sites for the parental NIH 3T3 cell line,
and the 3T3/16.1 control cells, respectively (Table I). At 6 wk,
the tumor incidence for these 2 cell lines reached 80% and
100%, respectively, demonstrating their high propensity to im-
plant and proliferate into nude mice. Surprisingly, the second
control clone, 3T3/14.3, did not give rise to any tumor until 6
wk after cell injection, and led to a tumor incidence of only





the endogenous mST3 RNA level of this clone was much
lower than those of the other 3T3 clones, suggesting clonal
variation in the parental 3T3 cell population, or that a re-
combination event leading to decreased ST3 gene expression,




 transfected cells, the clones 3T3/3.6, 3T3/2.1
and 3T3/1.1, which expressed very low levels or no AS mST3




), behaved similarly to the parental cell
line, although tumor appearance was slightly delayed with the
3T3/1.1 clone, which exhibited a tumor incidence of 71% after
8 wk of observation (Table I). The two other clones (3T3/7.5
and 3T3/4.6), however, exhibited a different pattern. First, no
tumor could be detected 3 wk after cell injection. Second, tu-
mor numbers were still low at 6 (14–20%) and at 8 (30–57%)
weeks (Table I). Since these clones expressed the highest lev-








), these findings sug-
gested that decreased mST3 expression could explain their
reduced tumorigenicity. Low levels of mST3 secretion by pa-
rental 3T3 cells together with a poor stability of mST3 (28, 43)
did not permit to precisely quantify the decrease in mST3 se-
cretion in 3T3 cells transfected with AS mST3 RNA. However,
using Western blot analysis, we could detect a low molecular
weight form of mST3 at 28 kD in 4 out of 10 samples of culture
media conditioned by parental 3T3 cells, but in none (0 out of
10) of those obtained from 3T3/7.5 transfected cells (data not
shown).
To further investigate the contribution of ST3 to tumorige-
nicity, we performed reverse experiments in which MCF7









), were stably transfected with a S mST3 cDNA in order
to produce recombinant mST3.
 
Increased tumor incidence using cells over-expressing
mST3.
 





 vector (Methods), and neomycin resistant
clones were screened for expression of mST3 using Northern
blot analysis. Three clones were found to express high













Figure 1. Northern blot analysis of NIH 3T3 cells transfected with an 
AS mST3 cDNA construct. (Lane 1) parental cells; (lanes 2 and 3) 
pCMV transfected cells; (lanes 4–8) pCMVASmST3 transfected cells. 
The position of the endogenous sense (S) and exogenous anti-sense 
(AS) mST3 transcripts are indicated. The 36B4 probe was used as a 
control for loading and transfer; autoradiography was for 2 d (mST3) 
and 18 h (36B4).
 
Table I. Tumorigenicity of Parental, pCMV and pCMVASmST3-transfected NIH 3T3 Cells, after S.C. Injection into Nude Mice
 
Clones Transfected vector S RNA* AS RNA*



























































1/7 (14%) 3/7 (43%) 5/7 (71%)




















 vs. the total number of injected mice, at the indicated time after cell in-
jection; corresponding percentages are indicated in parentheses.












) levels of mST3
RNA, whereas we could not detect any mST3 RNA in the








), even after a longer ex-
posure time (data not shown). By Western blot analysis, we
could detect mST3 protein in culture media conditioned by





















Both pro- and mature mST3 forms were detected together
with some degradation products, including the 28-kD form.
In vivo tumorigenicity of these cells was tested by S.C. in-




, the tumor incidence
in mice injected with MCF7 cells expressing mST3 was signifi-




 , 2 3 1025). Thus, 20 d after
cell injection, MCF7mST3/1, MCF7mST3/11 and MCF7mST3/
8 cells gave rise to a tumor incidence of 50–62%, whereas pa-
rental MCF7 cells and MCF7mST3/5 cells led to a tumor inci-
dence of 25 and 12%, respectively. This difference in tumor in-
cidence, which was still observed 35 d after cell injection, was
no longer apparent after 40 d when all cells, excepting
MCF7mST3/5, led to 100% tumors. Thus, the variation in tu-
mor incidence which was observed in these experiments in fact
corresponds to a reduction of the tumor-free period when
mST3-expressing cells were S.C. injected in mice. 
These findings were in good agreement with our hypothesis
that mST3 could promote tumorigenicity in nude mice. How-
ever, since differences have been observed between the func-
tional properties of mST3 and hST3 (28, 43), we tested whether
similar results could be obtained using MCF7 cells expressing
hST3.
Increased tumor incidence using cells over-expressing hST3.
Using the same protocol as described above, we obtained 3
MCF7 clones stably transfected with the pCMVhST3 vector
and expressing hST3 RNA (MCF7hST3/3, MCF7hST3/8 and
MCF7hST3/9; Fig. 3 A, lanes 4–6). These cells secreted both
pro- and mature hST3 in their culture media (Fig. 3 B, lanes 4–6).
In addition, we obtained two control clones (MCF7pCMV/1
and MCF7pCMV/2) transfected with the pCMV vector alone,
which did not express hST3 (Fig. 3, A and B, lanes 2 and 3). As
observed for mST3, hST3 expression was found to promote tu-
mor incidence in nude mice (log Rank test, P , 4 3 1024)
(Fig. 3 C). Similar results were also obtained using a clone
(MCF7hST3/13) stably transfected with a construct in which
hST3 was expressed under the control of the less potent SV40
Figure 2. Analysis of MCF7 cells expressing exogenous mST3 under 
the control of the CMV promoter. (A) Northern blot analysis: autora-
diography was for 1 day (mST3) and 18 h (36B4). (B) Western blot 
analysis of conditioned media: the positions of molecular weight stan-
dards, and of pro- and mature ST3 are indicated on the right and left, 
respectively. (A and B) lane 1, parental cells; lanes 2–5, pCMVmST3 
transfected cells. (C) tumor incidence after S.C. injection of parental 
and pCMVmST3 transfected MCF7 cells; n indicates the number of 
injected mice for each cell clone.
Figure 3. Analysis of MCF7 cells expressing exogenous hST3 under 
the control of the CMV promoter. (A) Northern blot analysis: autora-
diography was for 1 d (hST3) and 18 h (36B4). (B) Western blot anal-
ysis of conditioned media: the positions of molecular weight stan-
dards, and of pro- and mature ST3 are indicated on the right and left, 
respectively. (A and B) lane 1, parental cells; lanes 2–3, pCMV trans-
fected cells; lanes 4–6, pCMVhST3 transfected cells. (C) tumor inci-
dence after S.C. injection of parental, pCMV and pCMVhST3 trans-
fected MCF7 cells; n indicates the number of injected mice for each 
cell clone.
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promoter of the pSG5 vector, instead of the CMV promoter.
Low levels of hST3 RNA (Fig. 4 A, lane 2) and of the hST3 28kD
form (Fig. 4 B, lane 2) could be detected in MCF7hST3/13 cells
and culture media, respectively. Despite this low level of hST3
expression, MCF7hST3/13 cells led to an increased tumor inci-
dence (log Rank test, P , 4 3 1025). Thus, 20 d after cell injec-
tion, 75% of mice injected with MCF7hST3/13 cells exhibited
tumors whereas parental MCF7 cells gave rise to only 25%
(Fig. 4 C). 
ST3 over-expression did not modify cell growth and inva-
siveness. To define what could be the process leading to a re-
duction of the tumor-free period and thus to an increased tumor
incidence after S.C. injection of MCF7 cells expressing either
mST3 or hST3, we first evaluated tumor growth and cell prolif-
eration rates. We observed that once the tumors were estab-
lished, the evolution of tumor volumes was identical from one
cell clone to another, independently of the levels of ST3 ex-
pression. Consistently, no major differences were observed for
the in vitro cell proliferation rates whether or not the trans-
fected cells expressed mST3 or hST3 (data not shown). 
We next tested the invasive properties of transfected
MCF7 cells, both in vivo and in vitro. All clones grew as well
delineated tumor masses, and no evidence of local invasion
could be detected regardless of the tumor size. Moreover,
careful anatomopathological examination of mice did not re-
veal any lung or liver metastases, even after pS2 immunostain-
ing allowing the detection of isolated MCF7 cells (39). No his-
tological differences, notably concerning their vascular status,
were observed between tumors obtained in nude mice after in-
jections of either parental MCF7 cells or cells transfected with
pCMV, pCMVmST3 or pCMVhST3. Although the tumor
stroma was not as well developed as that of human breast car-
cinomas, we could observe areas where tumoral epithelial cells
were surrounded by fibroblastic cells after injection of ST3-
expressing (Fig. 5 A) or control MCF7 cells (Fig. 5 B). Endoge-
nous mST3 could not be detected in these fibroblasts, using an-
tibody 612 directed against mST3 (data not shown). MCF7
cells expressing recombinant ST3 protein were found to be ho-
mogeneously distributed throughout tumors, and staining was
restricted to the cytoplasm of transfected MCF7 cells (Fig. 5 C).
Northern blot (data not shown) and immunohistochemical
Figure 4. Analysis of MCF7 cells expressing exogenous hST3 under 
the control of the SV40 promoter. (A) Northern blot analysis: autora-
diography was for 4 d (hST3) and 18 h (36B4). (B) Western blot anal-
ysis of conditioned media: the positions of molecular weight stan-
dards are indicated on the left. In panels A and B: lane 1: parental 
cells; lane 2, pSG5hST3 transfected cells. (C) tumor incidence after 
S.C. injection of parental and pSG5hST3 transfected cells; n indicates 
the number of injected mice for each cell clone.
Figure 5. Histological and immunohistological analyses of tumors de-
rived from MCF7hST3/9 and control MCF7pCMV/1 cell clones. Tu-
mor sections were stained with hematoxylin and eosin (A and B) 
(X 60), or immunostained with polyclonal antibody 349 raised against 
hST3 (C and D) (360). (A and C) hST3-expressing MCF7hST3/9 
cells; (B and D) control MCF7pCMV/1 cells.
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(Fig. 5, C and D, and data not shown) analyses showed that the
levels of tumoral exogenous mST3 and hST3 RNAs and pro-
teins were in good agreement with those observed for the cor-
responding MCF7 clones, in vitro. Finally, the invasive proper-
ties of control and ST3-expressing cells were compared in the
type I collagen (41) and chick heart (42) invasion assays. The
expression of exogenous ST3 did not modify cell invasiveness.
Thus, neither ST3-expressing nor control cells invaded type I
collagen gels, and they resulted in the development of an orga-
nized non-invasive epithelioid layer at the periphery of the
heart tissue. We also tested the capacity of parental and trans-
fected cells to pass through matrigel-coated filters by using
Transwell chamber (40). Once again, no significant differences
were observed between cells expressing or not mST3 or hST3,
suggesting that ST3 expression did not confer cell invasive
properties, in these in vitro assays (data not shown). 
Discussion
In the present study, we investigated the role of ST3 in the de-
velopment of tumors after S.C. injection of malignant cells in
nude mice. We demonstrated that the incidence of tumors ob-
tained using malignant mouse fibroblastic NIH 3T3 cells,
which endogenously express ST3, was decreased when high
levels of AS mST3 RNA were expressed in these cells. In-
versely, we observed that human epithelial MCF7 breast can-
cer cells, which do not express endogenous ST3, showed signif-
icant increased tumorigenicity in nude mice when stably
transfected in order to produce mST3 (P , 2 3 1025). Similar
observation was made using MCF7 cells stably transfected in
order to express hST3 at either high levels under the control of
the CMV promoter (P , 4 3 1024) or at lower levels under the
control of the SV40 promoter (P , 4 3 1025). These studies
showed that the increased tumor incidences induced by either
mST3 or hST3 resulted from a shortening of tumor-free peri-
ods indicating that, in nude mice, ST3 is involved in tumor for-
mation rather than in tumor growth.
How could ST3 modulate tumor development in nude
mice? In vitro analyses of cell proliferation did not show any
obvious differences between ST3-expressing and non-express-
ing cells, suggesting that the observed increase in tumor inci-
dence could not be ascribed to an increased growth rate of
ST3-expressing cells. Consistently, once the tumors were es-
tablished in nude mice, their proliferation rates appeared to be
independent of their levels of ST3 expression. In addition, ST3
does not seem to be implicated in cell invasion, since MCF7
cells expressing ST3 did not exhibit any modifications of their
capacity to invade interstitial-like or basement membrane ma-
trices. Accordingly, no local invasion or metastatic spreading
was detected by histological analysis of tumors, lungs and liv-
ers of nude mice injected with ST3-expressing MCF7 cells.
Taken together, these findings indicate that ST3 expression
did not favor tumor incidence in nude mice by increasing cell
proliferation or invasion, but rather by increasing tumor take.
This is consistent with our finding that the increase in tumor
incidence observed for ST3-expressing MCF7 cells was more
pronounced in the first weeks after cell injection. Thus, we
propose that ST3 contributes to cell survival and implantation
in host tissues. This hypothesis may appear paradoxical with
regards to previous observations showing that ST3 was ex-
pressed during processes involving epithelial cell apoptosis
such as mouse mammary gland involution (25), mouse limb,
tail and snout morphogenesis (23) and frog metamorphosis
(24). However, while unwanted cells are eliminated during ap-
optotic events, some neighboring cells are selected for survival
(44 and references therein). In this respect, we note that ST3
gene expression is also observed at the time of epithelial cell
proliferation occurring in the neoformation of mammary ducts
following mammary gland involution (25), in developing limb,
tail and snout until birth (23), and in proliferative endometrium
(26). Interestingly, comparable observations have been re-
ported for matrilysin, another MMP implicated in cancer pro-
gression (1, 3). Thus, while SW480 colon cancer cells stably
transfected to express matrilysin did not show in vitro any
modification of their proliferative or invasive properties, these
cells exhibited increased tumorigenicity in vivo, suggesting
that the most significant role of matrilysin was at early stage of
tumor progression (14). 
Tumors that are obtained by S.C. injection of malignant
cells into nude mice should be regarded as a model for meta-
static implantation rather than for primary tumor development
(45). Indeed, S.C. injected cells mimic metastatic cells after ex-
travasation, when these cells have to successfully implant at
the metastatic site before being able to proliferate and invade
(45, 46). This process is dependent upon the cells’ capability to
survive in host tissues, either in an independent manner or by
the recruitment of required factors from their near vicinity. In
this context, ST3 may represent a local factor contributing to
the survival and implantation of ST3-expressing MCF7 cells
S.C. injected in nude mice. It appears reasonable to believe
that this might be also the case in human tumors, where ST3 is
produced by tumor stromal cells and not by the cancer cells
themselves (17–22). ST3 is a secreted protein which is specifi-
cally expressed by fibroblastic cells located in the vicinity of
cancer cells, suggesting that the same effects should be ob-
served irrespective of the source of the protein. Thus, in hu-
man carcinomas ST3 could act as a paracrine host factor con-
tributing to cancer cell survival outside of their compartment
of origin. Consistently, in normal embryonic and adult tissues
ST3 expression has been reported to occur during tissue re-
modeling processes, notably when, as in malignant processes,
the integrity of the basement membrane which separates epi-
thelial cell compartments from mesenchymal cells showed fail-
ure, leading to epithelial/stromal cell contacts (20, 23, 25, 26).
Although further studies are required to evaluate this possibil-
ity, a role for ST3 in favoring cell survival is consistent with ob-
servations demonstrating that high ST3 expression levels were
associated with metastatic propensity in human carcinomas
(22, 47).
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